This inventor holds 46 USPTO granted patents and 22 published patent applications, plus 2 CIPO patents and 13 EPO patents, primarily in Pharmaceutical Formulations. Top assignees: Sun Pharmaceutical Industries Limited, Sun Pharma Advanced Research Company Limited, Bioprojet. Active years: 2002-2026.
Location History:
- Tamil Nadu, IN (2003)
- Akota, IN (2008 - 2009)
- Vadodara, IN (2016)
- Mumbai, IN (2018)
- Baroda, IN (2002 - 2023)
- Gujarat, IN (2015 - 2024)
Company Filing History:
37 out of 155 
8 out of 66 
2 out of 24 
Years Active: 2002-2026
Areas of Expertise:
Title: Rajamannar Thennati: Innovator in GLP-1 Analogues from Baroda, India
Introduction
Rajamannar Thennati, based in Baroda, India, is a distinguished inventor recognized for his substantial contributions to pharmacology and biotechnology. With an impressive portfolio encompassing 42 patents, he has been instrumental in advancing treatment modalities for metabolic disorders, particularly diabetes and obesity.
Latest Patents
Among his recent innovations, Thennati has developed novel Glucagon-like Peptide-1 (GLP-1) (7-37) analogues. These analogues feature an amino acid sequence with Leucine or Isoleucine at the C-terminal, making them potent GLP-1 agonists. They exhibit reduced adverse effects and improved duration of action compared to previous iterations. Furthermore, the disclosure also highlights acylated derivatives of these analogues, which enhance potency and duration, suitable for oral administration. The applications of these analogues may significantly benefit patients suffering from diabetes and obesity.
Career Highlights
Thennati has played a vital role in organizations such as Sun Pharmaceutical Industries Limited and Sun Pharma Advanced Research Company Limited. His innovative spirit and expertise in the field have not only advanced patented technologies but have also contributed to the broader landscape of pharmaceutical research.
Collaborations
Throughout his career, Thennati has collaborated with other talented professionals, including Trinadha Rao Chitturi and Muthukumaran Natarajan. These partnerships have enriched his projects and fostered a collaborative environment for innovation and discovery.
Conclusion
Rajamannar Thennati continues to be a pivotal figure in the realm of pharmaceutical innovations. His work on GLP-1 analogues reflects his dedication to improving health outcomes for individuals affected by chronic conditions. With numerous patents to his name, Thennati's contributions are poised to make a lasting impact in the field of medicine.